SLC27A2 and neoplasm: Inhibiting FATP2 reduces lipids accumulation and reactive oxygen species (ROS) production, inhibiting immunosuppressive functions of MDSCs and improving anti-programmed death-ligand 1 (PD-L1) tumor immunotherapy effect [58].